Aslan Pharma raises US$34m in fresh funding
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
THE Republic's fledgling pharma ecosystem on Monday got a shot in the arm as biotech startup Aslan Pharmaceuticals announced it has raised US$34 million in Series C funding led by Accuron Technologies, a tech subsidiary of Temasek Holdings.
The proceeds, said Aslan, will be used to further accelerate clinical development of its pipeline of four novel therapeutic agents, all of which have the potential to treat tumour types "prevalent in Asia", such as gastric, bile duct and breast cancers.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Vietnam acts fast to shield firms, households from fuel price surge
Beijing’s calculated silence on the Iran war
S-E Asia tourism takes hit from Middle East crisis, but intra-regional travel could spell hope
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
